SpaceX IPO makes Elon Musk world's first trillionaire while major scientific facilities face funding cuts and breakthrough medical treatments advance globally.

SpaceX completes record $1.78 trillion IPO, making Elon Musk the world's first trillionaire, though analysts warn the valuation may have a 'major disconnect' on pricing and represents unprecedented wealth concentration in the space industry.

Britain's world-leading scientific facilities, including Diamond Light Source and ISIS Neutron and Muon Source, face potential cuts of up to 20% amid a £162 million funding crisis that experts warn could cause 'serious damage' to UK scientific capabilities.

Researchers reveal Venus flytrap's rapid-snap mechanism involves hair-trigger detection that causes outer leaf cells to soften, providing new insights into one of nature's most sophisticated predatory adaptations.

Global mapping of subterranean fungi networks reveals arbuscular mycorrhizal fungi systems exceed 100 quadrillion kilometers in total length, representing the planet's vast underground carbon circulatory system sustaining plant life.

Five lupus patients in England achieve remission following pioneering NHS trial using genetically modified T-cell therapy, offering potential cure for this chronic autoimmune disease affecting millions worldwide.

Neurological research reveals nearly all humans across cultures and ages exhibit natural counterclockwise walking bias regardless of dominant hand, with scientists still investigating the biological mechanism behind this universal directional preference.

Indonesian landslides fueled by climate-related severe storms devastate endangered orangutan populations, with studies estimating over 5% of the species lost in a single disaster event.

AI-powered weather forecasting research faces setback as National Science Foundation cuts funding for Amy McGovern's institute dedicated to improving extreme weather predictions during climate crisis intensification.

Controversial stem cell treatments targeting autistic children proliferate in the US, with desperate parents paying up to $20,000 per session for unapproved procedures that scientists characterize as potentially bogus and supported by figures like RFK Jr.

Debate intensifies over newer embryo gene-editing approaches as fertility specialists, biotech companies and ethicists clash over whether early genetic interventions prevent diseases or enable enhancement-focused designer babies.